Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

RBC Capital Maintains Outperform on EQB, Raises Price Target to C$85

RBC Capital analyst Geoffrey Small maintains EQB (TSX:EQB) with a Outperform and raises the price target from C$72 to C$85.
byBenzinga Newsdesk
February 21, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

RBC Capital analyst Geoffrey Small maintains EQB (TSX:EQB) with a Outperform and raises the price target from C$72 to C$85.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Intercept Announces Efficacy And Safety Data From Phase 3 REGENERATE Study In Liver Fibrosis Fue To NASH To Be Presented At NASH-TAG Conference 2023 Jan 6-7

By Benzinga Newsdesk
January 4, 10:08 AM
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced two abstracts on obeticholic acid (OCA) will be presented at the NASH-TAG Conference 2023.

ICPT